PI3K/AKT/mTOR通路
蛋白激酶B
PTEN公司
癌症研究
生物
细胞生物学
张力素
激酶
磷脂酰肌醇
癌细胞
癌症
信号转导
遗传学
作者
Mitsuhiko Osaki,M Oshimura,Hisao Ito
出处
期刊:Apoptosis
[Springer Nature]
日期:2004-10-25
卷期号:9 (6): 667-676
被引量:1189
标识
DOI:10.1023/b:appt.0000045801.15585.dd
摘要
Phosphatidylinositol-3-kinase (PI3K) is a lipid kinase and generates phosphatidylinositol-3,4,5-trisphosphate (PI(3, 4, 5)P3). PI(3, 4, 5)P3 is a second messenger essential for the translocation of Akt to the plasma membrane where it is phosphorylated and activated by phosphoinositide-dependent kinase (PDK) 1 and PDK2. Activation of Akt plays a pivotal role in fundamental cellular functions such as cell proliferation and survival by phosphorylating a variety of substrates. In recent years, it has been reported that alterations to the PI3K-Akt signaling pathway are frequent in human cancer. Constitutive activation of the PI3K-Akt pathway occurs due to amplification of the PIK3C gene encoding PI3K or the Akt gene, or as a result of mutations in components of the pathway, for example PTEN (phosphatase and tensin homologue deleted on chromosome 10), which inhibit the activation of Akt. Several small molecules designed to specifically target PI3K-Akt have been developed, and induced cell cycle arrest or apoptosis in human cancer cells in vitro and in vivo. Moreover, the combination of an inhibitor with various cytotoxic agents enhances the anti-tumor efficacy. Therefore, specific inhibition of the activation of Akt may be a valid approach to treating human malignancies and overcoming the resistance of cancer cells to radiation or chemotherapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI